Lisata Therapeutics, Inc. (LSTA) Dividend History

Company News

• Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why - Zacks Investment Research

  Lisata Therapeutics' lead pipeline candidate, certepetide, has shown promising results in a preclinical study for treating intrahepatic cholangiocarcinoma, an aggressive form of cancer. The positive data underlines the potential of certepetide in improving the tumor environment and making tumors more responsive to immunotherapy.

  Zacks Investment Research

  Featured Companies: ADPT ANIP RAPT
• Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

  Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX based therapies in pancreatic, colon and appendiceal cancers

  GlobeNewswire Inc.
• Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

  BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June:

  GlobeNewswire Inc.
• Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

  Seminal Phase 2b ASCEND trial top-line data expected in fourth quarter of 2024

  GlobeNewswire Inc.
• Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

  Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1 Results of Phase 1b/2 in China reinforce global clinical development rationale and plans for LSTA1

  GlobeNewswire Inc.